Hebei Changshan Biochem Pharma Tangible Net Worth Ratio
Hebei Changshan Biochem Pharma tangible net worth ratio. Hebei Changshan Biochem Pharma (300255) has a Tangible Net Worth Ratio of 48.3% as of September 2025. This metric is calculated by deducting intangible assets (CN¥764.41 Million) from net assets (CN¥1.48 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Check Hebei Changshan Biochem Pharma (300255) strategic investment index to assess the company's strategic physical and investment asset allocation.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Tangible Net Worth Ratio of Hebei Changshan Biochem Pharma (2008–2024)
Tangible net worth ratio of Hebei Changshan Biochem Pharma from 2008 to 2024. This chart shows how Hebei Changshan Biochem Pharma's Tangible Net Worth Ratio has changed across 17 annual periods from 2008 to 2024. As of September 2025, the ratio stands at 48.3%, reflecting net assets of CN¥1.48 Billion with intangible assets of CN¥764.41 Million CNY. See working capital to net assets of Hebei Changshan Biochem Pharma to evaluate short-term liquidity relative to the company's equity base.
Hebei Changshan Biochem Pharma Tangible Net Worth Ratio by Year (2008–2024)
Hebei Changshan Biochem Pharma tangible net worth ratio by year from 2008 to 2024. The table below presents the year-by-year Tangible Net Worth Ratio for Hebei Changshan Biochem Pharma from 2008 to 2024, covering 17 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For live market cap and overall valuation, see Hebei Changshan Biochem Pharma stock valuation.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 52.1% | CN¥1.54 Billion | CN¥735.99 Million | CN¥4.52 Billion | ▼ -10.1 pp |
| 2023 | 62.2% | CN¥1.80 Billion | CN¥680.24 Million | CN¥4.60 Billion | ▼ -19.9 pp |
| 2022 | 82.1% | CN¥3.05 Billion | CN¥547.95 Million | CN¥6.04 Billion | ▼ -1.9 pp |
| 2021 | 83.9% | CN¥3.07 Billion | CN¥493.13 Million | CN¥5.19 Billion | ▼ -2.0 pp |
| 2020 | 85.9% | CN¥2.85 Billion | CN¥401.78 Million | CN¥4.57 Billion | ▼ -3.7 pp |
| 2019 | 89.7% | CN¥2.72 Billion | CN¥281.27 Million | CN¥3.94 Billion | ▲ +0.1 pp |
| 2018 | 89.5% | CN¥2.52 Billion | CN¥264.17 Million | CN¥3.84 Billion | ▼ -0.1 pp |
| 2017 | 89.7% | CN¥2.44 Billion | CN¥251.76 Million | CN¥3.53 Billion | ▼ -1.6 pp |
| 2016 | 91.3% | CN¥2.29 Billion | CN¥199.11 Million | CN¥3.13 Billion | ▼ -0.3 pp |
| 2015 | 91.6% | CN¥1.57 Billion | CN¥131.59 Million | CN¥2.33 Billion | ▲ +0.9 pp |
| 2014 | 90.8% | CN¥1.43 Billion | CN¥131.92 Million | CN¥2.04 Billion | ▲ +1.3 pp |
| 2013 | 89.5% | CN¥1.29 Billion | CN¥135.19 Million | CN¥1.65 Billion | ▼ -3.9 pp |
| 2012 | 93.4% | CN¥1.13 Billion | CN¥74.35 Million | CN¥1.42 Billion | ▼ -0.9 pp |
| 2011 | 94.3% | CN¥987.45 Million | CN¥56.06 Million | CN¥1.19 Billion | ▲ +20.5 pp |
| 2010 | 73.9% | CN¥219.39 Million | CN¥57.37 Million | CN¥430.64 Million | ▼ -8.8 pp |
| 2009 | 82.7% | CN¥159.19 Million | CN¥27.59 Million | CN¥266.35 Million | ▲ +12.9 pp |
| 2008 | 69.7% | CN¥93.43 Million | CN¥28.27 Million | CN¥196.59 Million | — |